Cheng Yi Pharmaceutical Lidocaine Hydrochloride Injection Consistency Evaluation through Generic Drugs

Beijing Business Daily (Reporter Ding Ning) On the evening of April 3rd, Cheng Yi Pharmaceutical (603811) announced that the company had received the "Drug Supplement Application Approval Notice" approved and issued by the National Medical Products Administration. The company's produced lidocaine hydrochloride injection (specification: 5ml: 0.1g) has passed the quality and efficacy consistency evaluation of generic drugs.

The announcement shows that lidocaine hydrochloride injection is a local anesthetic and antiarrhythmic drug. Mainly used for infiltration anesthesia, epidural anesthesia, surface anesthesia (including mucosal anesthesia during thoracoscopy or abdominal surgery), and nerve conduction block. This drug can be used for ventricular premature beats and ventricular tachycardia after acute myocardial infarction, as well as for digitalis poisoning, cardiac surgery, and ventricular arrhythmias caused by cardiac catheterization.

Reprinted from:Beijing Business Daily